"
Team:UIUC-Illinois/Team/Advisors
From 2012.igem.org
(Difference between revisions)
| Line 171: | Line 171: | ||
<li>Entrepreneurship (New Venture Creation) Theory Strategy</li> | <li>Entrepreneurship (New Venture Creation) Theory Strategy</li> | ||
</ul> | </ul> | ||
| + | <br/> | ||
| + | <a href="https://netfiles.uiuc.edu/jabradly/www/">Click here for more information about this advisor.</a> | ||
</p> | </p> | ||
</td> | </td> | ||
| Line 184: | Line 186: | ||
<td width="790" valign="top" align="left"> | <td width="790" valign="top" align="left"> | ||
<p><center><font size="6">Dr. Zefeng Wang</font></p> | <p><center><font size="6">Dr. Zefeng Wang</font></p> | ||
| - | < | + | <br/> |
| + | Department of Pharmacology, University of North Carolina at Chapel Hill<br/><br/> | ||
| + | |||
| + | Research Interests: | ||
| + | <ul><li> | ||
| + | Identify splicing regulatory cis-elements and trans-factors (compiling the splicing code)</li> | ||
| + | <li>Develop new method to modulate splicing (debugging the splicing code)</li> | ||
| + | </ul> | ||
| + | <br/> | ||
| + | |||
| + | <a href="http://www.med.unc.edu/pharm/people/primaryfaculty/zefeng-wang/wang">Click here to learn more about this advisor.</a> | ||
</td> | </td> | ||
</tr> | </tr> | ||
Revision as of 03:40, 26 October 2012
